Working… Menu

A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01623518
Recruitment Status : Completed
First Posted : June 20, 2012
Last Update Posted : December 2, 2014
Information provided by (Responsible Party):
University of Oxford

Brief Summary:
This is a first in man dose escalation study, to assess the safety and immunogenicity of the candidate influenza vaccine ChAdOx1-NP+M1. All volunteers recruited will be healthy adults aged 18-50. Volunteers will be enrolled and doses will be escalated according to a "3+3" study plan. Up to 24 volunteers will be vaccinated. Following one dose of the vaccine, volunteers will be followed up to assess the side effect profile of the vaccine and to take blood tests. A series of immunology assays will be performed to determine how potent the vaccine is at inducing an immune response.

Condition or disease Intervention/treatment Phase
Influenza Biological: ChAdOx1-NP+M1 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1
Study Start Date : June 2012
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: ChAdOx1-NP+M1 Biological: ChAdOx1-NP+M1

Dose escalation in a 3+3 study plan;

5 x10^8 vp, 5 x10^9 vp, 2.5 x10^10 vp, 5 x10^10 vp

Primary Outcome Measures :
  1. Safety [ Time Frame: 3 weeks ]
    Analysis of data on adverse events.

Secondary Outcome Measures :
  1. Reactogenicity [ Time Frame: 3 weeks ]
    Immunogenicity endpoints will include interferon-gamma ELISpot as a marker of cell-mediated immunity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

The volunteer must satisfy all the following criteria to be eligible for the study:

  • Men and women aged 18-50
  • Resident in or near Oxford for the duration of the vaccination study
  • Able and willing (in the Investigators' opinions) to comply with all study requirements
  • Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
  • Willingness to use effective contraception for 4 weeks from the date of vaccination
  • Agreement to refrain from blood donation for 4 weeks from the date of vaccination
  • Written informed consent

Exclusion Criteria:

The volunteer may not enter the study if any of the following apply:

  • Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
  • Previous receipt of any recombinant adenoviral vectored vaccine
  • Previous receipt of MVA-NP+M1
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  • Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids are allowed)
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
  • Any history of anaphylaxis in reaction to vaccination
  • History of cancer (except basal cell carcinoma and cervical carcinoma in situ)
  • History of serious psychiatric condition
  • Any chronic illness requiring ongoing or awaiting hospital specialist supervision, other than minor surgical procedures and follow up of surgery over 6 months prior to screening.
  • Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week)
  • Seropositive for hepatitis B surface (HBsAg) or hepatitis C virus (antibodies to HCV)
  • Pregnancy, lactation or willingness/intention to become pregnant during the study
  • Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study.
  • No response / confirmation from GP regarding previous medical history

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01623518

Layout table for location information
United Kingdom
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
Oxford, United Kingdom, OX3 7LE
Sponsors and Collaborators
University of Oxford
Layout table for investigator information
Principal Investigator: Adrian Hill, MD University of Oxford
Layout table for additonal information
Responsible Party: University of Oxford Identifier: NCT01623518    
Other Study ID Numbers: FLU004
2012-000641-12 ( EudraCT Number )
First Posted: June 20, 2012    Key Record Dates
Last Update Posted: December 2, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Respiratory Tract Infections
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases